Clinical Trial

Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Study acronym: NIVOTHYM
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2017-04-26; most recent amendment 2026-05-13.
Status change: Recruiting → Active, Not Recruiting 2023-02-20
Status change: Not Yet Recruiting → Recruiting 2018-04-25
Trial Details
NCT Number NCT03134118
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: ETOP IBCSG Partners Foundation
Conditions Thymoma Type B3, Thymic Carcinoma
Enrollment 55 participants
Start Date 2018-04-11
Primary Completion 2023-09-05 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-15